Payer Coverage in Polycythemia Vera

Ken Schaecher, MD

Video Categories: Polycythemia Vera

Ken Schaecher, MD, Medical Director of SelectHealth, describes in his opinion how there is no payer coverage issues with patients with polycythemia vera at this time.

Supported through funding from Incyte
October 1, 2018

How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed

Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer [ Read More ]

March 31, 2015

Beginnings of Personalized Medicine for Myeloma

Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.